Opiant Pharmaceuticals, Inc. Common Stock
OPNT
OPNT was delisted on the 1st of March, 2023.
23 hedge funds and large institutions have $10.3M invested in Opiant Pharmaceuticals, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 5 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
0% more funds holding
Funds holding: 23 → 23 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
7% less capital invested
Capital invested by funds: $11.1M → $10.3M (-$779K)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$1.25M |
| 2 |
FM
Fondren Management
Houston,
Texas
|
+$1.15M |
| 3 |
GIP
Granite Investment Partners
El Segundo,
California
|
+$396K |
| 4 |
SIM
Spark Investment Management
New York
|
+$33K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$22.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$919K |
| 2 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$393K |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$352K |
| 4 |
BCM
Brasada Capital Management
Houston,
Texas
|
-$295K |
| 5 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$248K |
OPNT Hedge Fund Activity: Q1 2019 in Review
23 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Opiant Pharmaceuticals, Inc. Common Stock (OPNT) for Q1 2019, worth a combined $10.3M — down 7% from $11.1M a quarter earlier.
Fund positioning in OPNT was balanced in Q1 2019: 5 funds opened new positions, 5 closed out, 7 added to existing stakes and 6 trimmed.
The largest buyer was Broadfin Capital, opening a new position worth an estimated $1.25M. The largest seller was Stonepine Capital Management, cutting an estimated $919K.
- 23 institutional investors held Opiant Pharmaceuticals, Inc. Common Stock (OPNT) as of Q1 2019, unchanged from Q4 2018.
- Funds reported $10.3M of Opiant Pharmaceuticals, Inc. Common Stock stock for Q1 2019, down 7% quarter-over-quarter.
- 5 funds opened new Opiant Pharmaceuticals, Inc. Common Stock positions in Q1 2019 and 5 closed out, a net change of 0 holders.
- The largest Opiant Pharmaceuticals, Inc. Common Stock buyer in Q1 2019 was Broadfin Capital, an estimated $1.25M added.
- The largest Opiant Pharmaceuticals, Inc. Common Stock seller in Q1 2019 was Stonepine Capital Management, an estimated $919K sold.
Based on aggregated 13F filings for Q1 2019.